Full Text
PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)

Abstract

Authors

AA Fournier MS Duh Moyneur E Dial MP Neary WK Oh

Back to Volume 11, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×